Overview

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV)deoxyribonucleic acid (DNA) < 20 IU/mL at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Vir Biotechnology, Inc.

Treatments:

Nivolumab
Tenofovir